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Abstract 
Few studies have evaluated the association between DNA methylation in white blood 
cells (WBC) and the risk of breast cancer. The evaluation of WBC DNA methylation as a 
biomarker of cancer risk is of particular importance as peripheral blood is often available 
in prospective cohorts and easier to obtain than tumor or normal tissues. Here, we used 
pre-diagnostic blood samples from three studies to analyze WBC DNA methylation of 
two ATM intragenic loci (ATMmvp2a and ATMmvp2b) and genome-wide DNA 
methylation in LINE1 repetitive elements. Samples were from a case-control study 
derived from a cohort of high-risk breast cancer families (KConFab) and nested case-
control studies in two prospective cohorts: Breakthrough Generations Study (BGS) and 
European Prospective Investigation into Cancer and Nutrition (EPIC). Bisulphite 
pyrosequencing was used to quantify methylation from 640 incident cases of invasive 
breast cancer and 741 controls. Quintile analyses for ATMmvp2a showed an increased 
risk of breast cancer limited to women in the highest quintile (OR =1.89 (1.36-2.64), p= 
1.64x10-4). We found no significant differences in estimates across studies, or in 
analyses stratified by family history or menopausal status. However, a more consistent 
association was observed in younger compared to older women, and individually 
significant in KConFab and BGS, but not EPIC. We observed no differences in LINE1 or 
ATMmvp2b methylation between cases and controls. Together, our findings indicate 
that WBC DNA methylation levels at ATM could be a marker of breast cancer risk and 
further support the pursuit of epigenome-wide association studies of peripheral blood 
DNA methylation.  
Funding: Breast Cancer Campaign Fellowship and Cancer Research UK Program 
C536/A6689. Contributing study specific funding is noted in acknowledgments. 
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Introduction 
Dysregulation of epigenetic modification in tumour DNA such as hypermethylation of CpG 
islands at the promoters of hundreds of genes and global reduction of 5-methylcytosine (5-mC) 
levels has been observed in almost every cancer type (1). However, the roles of epigenetic 
modifications as risk factors for cancer and early disease biomarkers are yet to be determined 
(2). 
 
Epigenetic changes such as DNA methylation could be a biological indicator of lifetime 
accumulation of environmental exposures including ageing (3, 4), hormones (5, 6), ionizing 
radiation (7), alcohol (8), smoking (9, 10) and traffic particles (11). Alternatively, epigenetic 
changes might modify the effects of genetic susceptibility loci through genotype-epigenotype 
interactions, via in cis allele specific methylation (12). Some methylation changes may also 
reflect parental and early-life exposures that are particularly difficult to measure in 
epidemiological studies of adults (2, 13). Although DNA methylation profiles are often tissue and 
cell specific, recent data indicate that epigenetic traits in white blood cells (WBC) are promising 
candidate risk markers for solid tumors (14-16). Evaluating WBC DNA methylation as a 
biomarker of risk is of particular interest because peripheral blood DNA is comparatively 
accessible and is readily available in many large prospective epidemiological studies. Previous 
reports of WBC DNA methylation and cancer risk include studies of global DNA methylation 
levels in repeat regions across the genome (e.g LINE1, Alu) or 5-mC content in genomic DNA 
(16-20); studies of gene-specific DNA methylation levels in candidate genes (14, 21-29), and 
genome-wide DNA methylation microarray studies (15, 30-32). Although these studies provide 
enticing findings, most included relatively small study populations and/or used samples 
collected after diagnosis thus raising concerns about reverse causality and the potential 
confounding influences of active disease or treatment on DNA methylation in blood (25).  
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Most research on DNA methylation in cancer has focused on gene promoter CpG islands 
(CGIs). Reasons for this include the historical identification of methylation at the promoters of 
tumor suppressor genes in a wide variety of cancers, and the mechanistic association of 
methylation with transcriptional repression at these loci (33). However, recent data suggest that 
methylation in regions around CpG islands or “shores” and intragenic sequences also appears 
to be important in tissue specific expression, and may be an important contributor to inter-
individual variation in gene expression (34). For example, using a differential methylation 
hybridisation microarray analysis of candidate genes in WBC DNA, we showed that the majority 
of methylation variability in 55 genes was associated with intragenic repetitive elements (14). In 
addition, an intragenic differentially methylated region (DMR) within the ATM gene correlated 
with gene expression and was significantly more methylated in post-diagnostic blood samples 
from 190 bilateral breast cancer cases compared with 190 controls (14). However, global DNA 
methylation as measured by LINE1 repetitive element methylation was not significantly 
associated with risk. In the present study, we followed up these findings to test the hypothesis 
that pre-diagnostic intragenic and global LINE1 repetitive element methylation is prospectively 
associated with the risk of breast cancer using three studies with pre-diagnostic blood samples: 
the Kathleen Cuningham Foundation Consortium for Research into Familial Breast cancer 
(KConFab) study, a prospective cohort of families at high risk of breast cancer; and two general 
population prospective cohorts: the Breakthrough Generations Study (BGS) and the European 
Prospective Investigation into Cancer and Nutrition (EPIC).   
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Materials and Methods 
Study Populations 
Study participants were drawn from three large studies with blood samples collected prior to 
breast cancer diagnosis (Table 1). All contributing studies have appropriate ethical approval for 
sample and data collection. The first study was provided by KConFab (35). From 1997 to May 
2011, KConFab collected peripheral blood samples from 12,747 members of 1,395 families 
(~8.8 samples per family) in Australia and New Zealand. Families had an average of three 
verified (5.4 unverified) breast cancers per family. At the time of sampling there were 12,747 
blood samples collected from breast cancer family members of whom 4305 had a verified prior 
cancer diagnosis. All remaining healthy subjects were screened for subsequent incident cancer 
cases which were identified and confirmed in one of four ways, primarily by clinical pathology 
report, then doctor’s notes, cancer council registry verification or death certificate. Incident 
cases of invasive breast cancer were selected for this study from all individuals with a breast 
cancer diagnosis >1 month after blood sample collection (n=171). Five cases of non-white 
ethnicity were excluded from the analyses resulting in 166 invasive cases that were compared 
to 225 healthy unrelated controls without a family history of breast cancer drawn from “best 
friends” of subjects enrolled in KConFab. Incident breast cancer cases had blood samples 
taken, on average, 45 months prior to diagnosis (range 1 to 140 months). Information on breast 
cancer risk factors including hormonal and reproductive factors, cigarrette smoking and alcohol 
drinking was collected from questionnaires at enrollment. In addition, pathology data included 
grade (12% grade I, 33% grade II, 40% grade III), nodal status (37% node positive), ER (63% 
ER positive, 24% ER negative), PR (55% PR positive,  HER2 status (27% HER2 positive) and 
BRCA1/2 mutation status (23% BRCA1 mutant, 14% BRCA2 mutant, 63% non-BRCA1/non-
BRCA2) was available for breast cancer cases.  
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The second study was based on the BGS, a large general population cohort consisting of 
~110,000 women enrolled in the UK from 2003 to 2011 (36) . Study participants were sampled 
from a nested case-control study of all incident cases of breast cancer diagnosed in the BGS up 
to June 2010 and controls individually matched on recruitment source, year of completion of the 
baseline questionnaire at enrolment, ethnicity (white only), date of birth within 12 months, 
availability of blood sample and duration that the blood sample was in the mail. Breast cancer 
cases were self-reported in a follow-up questionnaire about 2.5 years after enrollment or notified 
by study participants by phone or letter. Self-reported diagnoses were confirmed through an 
electronic linkage with England/Wales/Scotland/Northern Ireland cancer registrations (or by the 
general practitioner for a small number of cases that could not be successfully linked).  Checks 
against UK cancer registrations were also made for those BGS participants known to have died 
by the time of the 2.5 year follow-up, or who otherwise failed to respond to the follow-up but had 
given permission for such follow up. A random sample of 257 case-control pairs out to 534 pairs 
identified as of December 2010 was selected for the methylation study. Four controls that were 
subsequently found to have had prevalent breast cancer at study entry, 3 cases whose blood 
was collected after diagnosis and 1 case with ductal carcinoma in situ (DCIS) were excluded 
from the analyses, resulting in a total of 253 cases and 253 controls available for analyses. 
Blood samples, from incident cases, were taken on average 18 months before diagnosis (range 
0.03-59) (Table 1). Extensive information on breast cancer risk factors was collected from a 
baseline questionnaire at enrollment. Pathology information from all cases was not available at 
the time of these analyses, available data represents only 25% of cases and included 
morphology (78% ductal, 12% lobular, 10% other), grade (14% grade I, 50% grade II, 36% 
grade III), nodal status (33% node positive), ER status (84% ER positive, 16% ER negative) and 
HER2 status (19% HER2 positive). An additional random sample of 92 participants in the BGS 
were selected from women enrolled in 2004 with two blood samples/questionnaires collected at 
baseline and first follow up (~6 years after baseline). Additional inclusion criteria included: 35-84 
Brennan et al,  ATM intragenic methylation as a breast cancer risk marker - 7 - 
 
years at enrollment, free of breast cancer prior to second blood collection, not know to be have 
a relative in the study, blood samples received at processing lab <1 day after collection, 
expected amount of blood receipt at the lab, no reported problems at collection or processing 
(e.g. lipeamic, heamolyzed, clotted samples), and time between the receipt of each sample 
between 5.5 and 6.5 years. Paired samples from these women were analyzed to evaluate the 
stability of the ATMmvp2a and LINE1 methylation markers over time.  
 
The third study was provided by the European Prospective Investigation into Cancer and 
Nutrition (EPIC) cohort, a large general population cohort consisting of ~520,000 individuals 
with standardized lifestyle and personal history questionnaires, anthropometric data and blood 
samples collected for DNA extraction (37). Study participants were sampled in two groups 
including a group of premenopausal women (145 cases and 145 controls) and post-menopausal 
women (139 cases and 146 controls), with menopausal status defined at the time of blood 
collection. Controls were individually matched on age at baseline, recruitment centre, date and 
time of blood collection. DCIS cases were excluded from analyses (n=36) resulting in a total of 
248 cases and 291 controls available for analyses (Table 1). We did not have precise ethnicity 
data on these individuals, however, the majority (80%) of individuals were provided from Italy, 
Spain and the Netherlands and the remainder (20%) were provided from France, Germany, UK 
and Greece. Blood samples from cases were taken on average 55 months before diagnosis 
(range 24-108) (Table 1). Extensive information on cancer risk factors including extensive 
alcohol, smoking and dietary data, family history and hormonal factors were collected from a 
baseline questionnaire at enrollment. Pathology information on cases included morphology 
(73% ductal, 14% lobular, 13% other), grade (15% grade I, 65% grade II, 20% grade III), stage, 
ER (79% ER positive, 21% ER negative), PR (62% PR positive, 38% PR negative) and HER2 
status (20% HER2 positive). 
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Laboratory methods 
DNA samples were extracted from whole blood using Qiagen DNA blood Mini Kits in KConFab. 
DNA samples from BGS and EPIC were extracted from buffy coats using DNA Blood Mini Kits 
(Qiagen, UK), except for 29 cases and 15 controls in BGS extracted using Nucleon Genomic 
DNA Extraction Kit (Tepnel, Life Sciences, UK). 500 ng of DNA (KConFab) or 250ng (BGS and 
EPIC studies) from each subject was bisulphite converted using EZ-96 DNA Methylation-Gold 
kit according to the manufacturer’s protocol (Zymo Research, Orange, CA). Methylation analysis 
of long interspersed nuclear element-1 (LINE-1) was analysed using commercially available 
LINE1 primers (Qiagen, UK). Primers and PCR conditions for ATMmvp2a and ATMmvp2b 
regions were as described previously (14). Methylation values were calculated as an average of 
all high quality CpG sites (determined as “passed” by the quality control thresholds within the 
Pyro Q-CpG Software (Qiagen, UK)). The Pyro Q-CpG Software has inbuilt overall quality 
assessment for each sample which flags any sequence that deviates from the expected pattern. 
Any sample failing quality control was removed from the analysis. The number of samples 
failing in each assay were ATMmvp2a (55/1436 subjects), ATMmvp2b (56/1436 subjects) and 
LINE1 (87/1436 subjects). Additionally, a commercially available fully methylated genomic DNA 
sample was used as a positive control (Zymo Research, Orange, CA) and in-house whole 
genome amplified genomic DNA (Genomiphi, GE Healthcare) used as an unmethylated 
negative control. The percentage of cells with methylated DNA at each of the loci was 
calculated as the average of 3 (ATMmvp2a) or 4 (LINE1 and ATMmvp2b) CpG sites and was 
used as the measure of methylation for each subject. Based on previous experimental results 
the range for a typical assay is 90-98% for the positive control and 1-6% for the negative 
control. Further quality assurance was performed with blinded duplicate samples (12 pairs) in 
the BGS and reference controls on each plate with median differences (intraclass correlation 
[95%CI] in brackets) of 2.1% (ICC=0.99 [0.98-1.00], p=5.0e-37), 3.4% (ICC=0.97 (0.94-0.99), 
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p=1.8e-15), 1.8% (ICC=0.98 [0.97-0.99], p=1.6e-25) for ATMmvp2a, ATMmvp2b and LINE1, 
respectively.  
 
Statistical Analysis  
The Wilcoxon test for matched pairs was used for BGS and EPIC and the Mann-Whitney U test 
was used for KConFab, to test for differences in median methylation levels between cases and 
controls. Levels of methylation across studies were standardised using Z-scores that were 
categorised in quintiles based on their distribution in the combined control population. Logistic 
regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for 
individuals in the 2nd, 3rd, 4th and 5th methylation quintiles, compared with individuals in the 1st 
(lowest) quintile. Analyses of combined data from all studies were adjusted by age in 5-year 
categories and study. Age at blood draw, age at menarche, parity, age at menopause, alcohol 
consumption, body mass index (BMI), oral contraceptive and hormone replacement use and 
family history of breast cancer were considered as potential confounders. Analyses were 
stratified by age at blood drawn using tertiles of the combined control population (21-49, >49-59, 
>59-91), family history and time from blood collection to diagnosis to evaluate effect 
modification by these variables. Estimates from conditional logisitic regression models for 
individually matched pairs in BGS (n=241 pairs after QC) and EPIC (n=221 pairs after QC) were 
similar to estimates from unconditional logistic models adjusted or unadjusted by matching 
factors. Only findings from the unconditional logistic analyses are presented to avoid loss of 
data from exclusion of pairs with one member excluded because of missing methylation data or 
other reasons (see Study Population section). Heterogeneity of estimates by study was tested 
by including an interaction term for the biomarker and an indicator variable for study in the 
logistic model. Random-effect meta-analyses of estimated ORs from all studies in this report 
and a previously published study were performed in R using the “metafor” package (38). 
Polytomous logistic regression models with categories of methylation levels as the outcome 
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variable were used to test for associations between methylation levels and the breast cancer 
risk factors specified above, adjusted for age. B- spline quadratic logistic regression models 
fitted in the “bs” R package were used to explore the relationship between continuous measures 
of methylation levels and breast cancer risk . All statistical tests were performed using R (v 
2.12.0).  
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Results 
For the ATMmvp2a locus we observed significantly higher median methylation in cases than 
controls in the familial samples from KConFab (81.8% vs 76.9%, p=4.87x10-6; Table 2) and 
marginally higher median methylation in the population-based cases from BGS compared with 
controls (76.8% vs 76.4%, p=0.02). In the EPIC cohort we observed no significant differences in 
median methylation levels in cases compared with controls (75.7% vs 76.1%, p=0.40). In BGS 
and KConFab we observed an upward shift in the distribution of methylation in cases compared 
with controls, which was not observed in EPIC (Supplementary Figure 1). No significant 
differences were found for methylation levels at the ATMmvp2b locus (131bp downstream from 
ATMmvp2a) or LINE1 in any of the studies (Table 2). 
Quintile analyses for the ATMmvp2a locus, adjusted by age at blood collection in 5 year 
categories, showed a significantly increased risk of breast cancer for women in the highest 
quintile compared with the lowest quintile in the BGS and KConFab studies, but not in EPIC 
(Table 3). Further adjustment by age as continuous variable and conditional logistic analyses for 
paired samples individually matched in BGS and EPIC showed similar results (Supplementary 
Table 1). Analyses of combined data from all studies adjusting by study and age at blood 
collection indicated that women in the highest quintile (>6.3% methylation above study mean 
methylation) were at 1.9-fold increased risk of breast cancer compared with women in the 
lowest quintile (OR=1.89 (1.36-2.64), p=1.64x10-4) (Table 3). While the overall difference in 
median levels between cases and controls was small (1.1%), the difference in median 
methylation between the highest quintile (86%) and lowest (65%), where the association with 
cancer status is observed was large (21%). A quadratic B-spline regression model of continuous 
levels of methylation at ATMmvp2a and breast cancer risk confirmed a threshold association, 
rather than a linear association, between methylation levels and breast cancer risk 
(Supplementary Figure 2). 
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Study-adjusted analyses stratified by age at blood collection suggested a weaker ATMmvp2a 
risk association when methylation was measured in samples collected from women >59 years 
of age (Table 4). Similar results were obtained when stratified by age at diagnosis (data not 
shown). However, age-specific estimates within study revealed that the weaker association was 
driven by the EPIC cohort that showed no increased risk in this age subgroup (Supplementary 
Figure 3). Overall analyses showed some evidence for heterogeneity of estimates between 
studies (Table 3; P-value for test for heterogeneity=0.07). This evidence was limited to women 
in the older age group and there was no evidence for study heterogeneity within the younger 
age subgroups (p-value for study heterogeneity by age subgroups 21-49 (p=0.51), 50-59 
(p=0.72), 60-91 years (p=0.09)). We observed a significant association between ATMmvp2a 
methylation levels and increasing age at blood collection in controls (Spearman’s rho=0.15, 
p=0.0015), but not in cases (Spearman’s rho=-0.02, p=0.43), that was most significant in the 
EPIC cohort (rho=0.11, p=0.007) compared to KConFab (rho=0.06, p=0.26) and BGS 
(rho=0.02, p=0.40). This underlying age association may account for the apparent cross-over 
risk association with ATM methylation by age at blood collection seen in EPIC (Supplementary 
Figure 3).  Analyses by menopausal status at blood collection, adjusted by study and age, 
showed similar risk estimates for pre- and post-menopausal women (Supplementary Table 2).  
 
Adjustment by breast cancer risk factors (age at menarche, menopausal status at blood drawn, 
parity, age at menopause, alcohol consumption, body mass index, oral contraceptive and 
hormone replacement use and family history of breast cancer) did not result in appreciable 
changes in relative risk estimates for any of the markers across the three studies in this report. 
Consistently, these risk factors were not significantly associated with ATMmvp2a methylation 
levels in any of the three control populations (data not shown). In the familial cases from 
KConFab, we found no significant associations between ATMmvp2a methylation levels and 
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BRCA1/2 mutation status, tumour pathology (morphology, grade, node status, ER, PR and 
HER2 status) (data not shown). Similarly in EPIC and BGS samples we found no significant 
association with available data on tumour pathology (data not shown).  
 
Analyses stratified by time from blood collection to diagnosis (<=1 year vs >1 year) showed no 
significant differences in effect estimates using the combined data (Supplementary Table 3). 
Consistently, linear regression analyses of methylation levels and time from blood collection to 
diagnosis, adjusted by age, showed no significant associations (KConFab p=0.97; BGS p=0.10, 
EPIC p=0.28), over the range of 0-11 years studied here.  
 
A biomarker for risk that is observed only at one time point (as is the case with most case-
control studies) would ideally be stable over time. We measured the stability of the ATM mvp2a 
marker and LINE1 by assessing methylation in a control population where blood samples were 
taken 6 years apart from the same individuals in the BGS cohort (n=92 pairs). Using conditional 
logistic regression we observed no significant change in either ATM mvp2a (median change = 
0.19%, p= 0.51) or LINE1 (median change = 0.27%, p= 0.69) over 6 years. The ATM variation 
between individuals is much larger than within individuals at two time points (ICC=0.57; 
between time points correlation R2= 0.79) and there are no significant differences between 
measurements in the two time points (paired T-test, p=0.24; signed test for H0:median 
difference=0 , p=0.74).  These data demonstrate that the ATM methylation is stable for at least 
~6 years.   
We previously reported a quartile analysis of the ATMmvp2b region in bilateral breast cancer 
patients which showed a 3-fold higher chance of being a breast cancer case compared with 
healthy controls in the highest quartile (14). We have now re-analyzed these data for both loci 
(ATMmvp2a and ATMmvp2b) using a quintile analysis for direct comparison to the present 
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study. This analysis shows that women in the highest quintile of methylation had increased 
bilateral breast cancer risk for both ATMmvp2a (age-adjusted OR=1.90 (95% CI=1.00-3.62), 
p=0.05) and ATMmvp2b (age-adjusted OR=3.07 (95% CI=1.58-5.93), p=8.8x10-4) 
(Supplementary Table 4). A meta-analysis of odds ratio estimates including the three additional 
studies and the study of bilateral breast cancer cases, suggested that the methylation levels in 
the ATMmvp2a marker is associated with 1.89-fold odds ratio (95% CI 1.27-2.82, p=1.7x10-3, 
random effects model) for women in the 5th quintile compared to the 1st quintiles 
(Supplementary Figure 2), with no significant heterogeneity between studies (p=0.15).  
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Discussion 
Our findings indicate that high levels of methylation in the ATM DMR might be a biomarker of 
breast cancer risk. To our knowledge, this is the first report to identify a significant association 
between breast cancer risk and gene-specific methylation in WBC DNA measured in pre-
diagnostic blood samples from cases in prospective cohorts, and using pyrosequencing which is 
a highly quantitative method. 
Previous studies investigating peripheral blood methylation variability in relation to cancer risk 
have focused mainly on rare epimutations or genome-wide methylation levels (25, 39). Only a 
few studies have investigated gene specific DMRs and all of these have been carried out in 
small retrospective studies or used non-quantitative methods (26-29). This includes our initial 
report of the association between ATM hypermethylation in WBC DNA and increased breast 
cancer risk using retrospectively collected blood samples from bilateral breast cancer patients 
(14).  While findings for ATMmvp2a were consistent with those in this report, the strong 
association found for ATMmvp2b in the bilateral study was not replicated. Differences in findings 
could be due to the different designs and study populations, e.g. use of pre- versus post- 
diagnostic blood samples, source of control populations, and inclusion of incident versus 
prevalent cases, or bilateral versus mostly unilateral breast cancers.  
The main strength of the current report is the inclusion of three independent study populations. 
Although we found no significant heterogeneity in ATMmvp2a risk associations across studies, 
the evidence was strongest for KConFab and weaker for the BGS and, particularly, for the EPIC 
cohort.  The stronger association in KConFab could be explained by the inclusion of cases with 
very strong family histories, and/or to the choice of controls that were selected from best friends 
of KConFab participants, and had no family history of breast cancer. In contrast, BGS and EPIC 
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are nested case-control studies within two general population cohorts, thus ensuring that cases 
and controls come from the same source population. We observed a weak correlation between 
increasing methylation and increasing age at blood draw in the control populations, as has been 
shown for numerous methylation markers in blood (3, 4).  The age correlation was particularly 
strong in the EPIC cohort, which might explain that the risk association in this cohort was not 
seen in women with bloods collected at older ages. It is important to note that breast cancer 
cases in KConFab were younger than controls, therefore, if there was no real association with 
risk, an association between increasing age at blood collection and increasing methylation 
would result in an observed inverse association, rather than a positive association that we 
found. The fact that the ATM risk association was most robust and consistent across studies for 
women with bloods collected in younger ages, suggests that this finding may be more 
applicable to women in this group, or to breast cancer cases with earlier onset. However, 
additional data is needed to confirm this potential effect modification by age since differences 
were not statistically significant in our analyses. We can speculate that if ATM hypermethylation 
is associated with an endogenous increased risk of breast cancer, then it is plausible that it 
would be more frequent in earlier onset breast cancer cases, similarly to genetic mutations, and 
we would thus have an ascertainment bias towards finding this association in younger 
compared to older women. Larger sample sizes from studies with long follow up will be required 
to separate out the associations among women with blood drawn at a young age from those 
associated with earlier onset breast cancer. 
The use of pre-diagnostic samples from incident breast cancer cases in this report excludes the 
possibility that methylation variability in WBC DNA was influenced by the presence of clinical 
cancer or treatment in these patients. Further, we found no association between time from blood 
collection to diagnosis and level of ATM methylation, indicating that findings are unlikely to be 
explained by pre-clinical disease effects (range of time from blood collection to diagnosis in our 
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studies was <1month to 11 years). Furthermore, using serial blood samples taken 6 years apart 
we have shown that this marker appears to be stable over time. Thus, data suggest that ATM 
hypermethylation in WBC DNA represents a stable marker of predisposition rather than an early 
tumorigenic event that increases with increasing tumor burden. 
The strongest association between ATM methylation and breast cancer risk was observed in the 
KConFab study which is a familial breast cancer cohort that includes an over representation of 
BRCA1 and BRCA2 mutation carriers. We have previously shown that BRCA1 mutant tumours 
have much lower levels of gene-specific hypermethylation than non-BRCA1/BRCA2 or BRCA2 
mutant tumours (40). This suggests that BRCA1 mutations may lead to an overall disturbance in 
methylation patterns. To support this hypothesis, a recent study has shown that young girls with 
a strong family history of breast cancer have significantly lower levels of white blood cell DNA 
methylation of ALU and LINE1 repetitive elements than young girls without a strong family 
history (41). However, in contrast to this finding, we found no differences between methylation 
levels of LINE1, or ATM in carriers of BRCA1 (n=39), BRCA2 (n=23) mutations compared to 
non-carriers (n=104) in the KConFab adult cases (data not shown). In addition, we found no 
association between methylation in LINE1 or ATM and family history of breast cancer in BGS 
and EPIC controls (data not shown), thus not supporting a strong association between 
methylation and family history. Further work on larger numbers of mutation carriers will be 
required to determine if these do indeed have an overall aberrant methylation defect.  
The association between breast cancer risk and methylation of an intragenic repetitive element 
in ATM is consistent with a previous study in which the majority of cancer associated CpG sites 
were found in intragenic sequences (42).  Furthermore, we have previously shown that greater 
methylation variability occurs within gene bodies than within promoters (14). Several 
hypotheses have been proposed for how intragenic DNA methylation regulates transcription via 
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mechanisms including transcription rate, nucleosome positioning, alternate start sites, 
replication timing or chromatin marks (42). Therefore, these data raise the possibility that 
phenotypic variability such as gene expression variability and indeed cancer susceptibility may 
be influenced by regions of DNA methylation variability, such as intragenic repetitive elements, 
moreso than unmethylated regions of low variability such as CpG islands.  
The mechanism by which methylation at ATMmvp2a could increase risk is not known. We have 
previously shown in cancer cell lines, that hypermethylation of the nearby locus ATMmvp2b is 
associated with reduced ATM expression (14), but expression analysis in cell lines and blood 
samples is needed to examine the effect of ATMmvp2a hypermethylation on ATM expression. 
Interestingly, expression of ATM in WBCs of breast cancer patients and controls, at the time of 
mammographic screening, showed significantly reduced expression in breast cancer patients 
(n=51) compared with controls (n=31) in a recent study (43) (Supplementary Figure 4). These 
data support the hypothesis that reduced expression of ATM, detectable in WBCs, may be 
linked to breast cancer susceptibility. 
 
Genome-wide DNA hypomethylation has been linked to bladder cancer risk in three relatively 
large case-control studies (285 to 775 cases) (16-18). In addition, genome-wide 
hypomethylation has been linked to the risk of head and neck squamous cell carcinoma (19), 
while two relatively small studies (40 cases versus 40 controls and 179 cases versus 180 
controls) suggested an association with breast cancer (20, 39). In our previous study we 
showed no significant difference between 190 breast cancer cases and 190 controls using the 
LINE1 repetitive element in WBC DNA methylation (14). Consistent with these findings, we 
found no evidence of association between LINE1 methylation and breast cancer risk in any of 
the three studies in this report. Inconsistencies between our findings and those reporting 
associations between blood genome-wide hypomethylation and cancer risk may be due to 
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smaller sample sizes (20, 39), the use of post-diagnostic DNA samples in previous studies (20, 
39), different cancer types (16-18), and different methods using other repetitive elements (20, 
39) or total 5-methylcytosine (16-18).  
 
In conclusion, our findings on the association between ATM hypermethylation in WBC DNA 
prior to diagnosis and the risk of developing breast cancer provide further support for the 
investigation of common epigenetic variability as risk markers for breast and other cancers. In 
addition to candidate-gene studies, Epigenome-wide Association Studies (EWAS) are now 
possible with the development of high-throughput technology that allows high-resolution 
analysis on a genomic level (15, 32, 44). However, adequately powered studies with blood 
samples collected prior to diagnosis will be critical for the success of both candidate and 
epigenome-wide approaches to discover epigenetic biomarkers of cancer risk. 
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Figure Legend 
 
Figure 1: Meta-analysis of ATM methylation in four cases – control studies. A) Methylation 
levels at ATMmvp2a were separated into control quintile ranges (using identical ranges from 
combined analysis), for the previously published report on the British Breast Cancer Study 
(BBCS ‡) (14) and the three new case-control studies. Odds ratio of Qi5 vs Qi1 is shown. 
Combined overall analysis was determined using a random effects model.  
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Table 1: Characteristics of the study populations* 
 KConFab BGS** EPIC***
 Controls Cases Controls Cases Controls Cases
N 225 166 253 253 291 248
Age at blood draw in 
years, mean (range) 60 (33-83) 50 (21-91) 54 (23-82) 54 (23-82) 52 (33-76) 52 (33-76) 
Family History, N (%)       
    Yes 0 (0%) 166 (100%) 51 (20%) 69 (27%) 24 (14%) 23 (18%)
    No 225 (100%) 0 (0%) 201 (80%) 183 (73%) 144 (86%) 108 (82%)
Menopausal status at 
blood draw, N (%)       
     Pre-menopausal 37 (17%) 101 (65%) 135 (61%) 134 (62%) 145 (50%) 127 (50%)
     Post-menopausal 183 (83%) 54 (35%) 87 (39%) 83 (38%) 146 (50%) 121 (50%)
Time from blood 
collection to diagnosis 
in months, mean 
(range) - 45 (1-140) - 18  (<1-59) - 55 (24-108) 
Age at diagnosis, mean 
(range) - 52 (29-88) - 55 (23-84) - 57 (37-80) 
 
* Cases were individually matched to controls for recruitment source, year of completion of the baseline 
questionnaire at enrolment, ethnicity, availability of blood sample and date of birth within 12 months and duration 
that the blood sample was in the mail. 
** Cases and controls were selected within strata of menopausal status (pre- and post-) and individually matched 
on age, recruitment centre, date and time of blood collection. 
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Table 2: Distribution of methylation levels in ATMmvp2a, ATMmvp2b and LINE1 in breast 
cancer cases and controls  
 
Assay Study Contr
ol 
Case Control Case **
N* N* Median IQR Median IQR P-value
ATMmvp2a BGS 248 249 76.4 70.2-80.2 76.8 70.9-82.7 0.02
 EPIC 283 235 76.1 70.5-80.6 75.7 70.0-80.8 0.40
 KConFab 210 156 76.9 71.6-81.5 81.8 75.8-86.5 4.87x10-6
ATMmvp2b  BGS 234 248 91.0 87.0-94.8 91.4 85.6-95.0 0.61
 EPIC 287 240 92.2 87.3-95.2 92.3 88.3-95.7 0.36
 KConFab 208 162 92.6 87.2- 96.3 92.3 82.4-96.5 0.24
LINE1 BGS 242 241 79.0 77.9-80.1 79.0 78.1-79.9 0.96
 EPIC 263 232 75.1 73.9-76.3 75.2 73.9-76.3 0.89
  KConFab 218 153 76.0 74.3-78.0 76.6 75.2-77.6 0.20
 
* Differences in numbers of cases and controls within each study with total numbers are due to missing 
data (failed QC) on methylation markers.  
** Wilcoxon matched pairs test for BGS and EPIC and Mann-Whitney U-test for KConFab 
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Table 3: Association between methylation levels in ATMmvp2a and breast cancer risk in 
BGS, EPIC, KConFab and Combined analysis  
   Controls Cases    
Study Quintile* Meth Range N Freq. N Freq. OR** 95%CI P-value 
BGS Qi1 3.4 - 68.0% 50 0.20 35 0.14 1.00   
 Qi2 68.0 - 74.1% 40 0.16 46 0.18 1.56 0.85-2.88 0.15 
 Qi3 74.1 - 77.6% 54 0.22 47 0.19 1.15 0.66-2.16 0.54 
 Qi4 77.6 - 81.0% 56 0.23 42 0.17 1.00 0.55-1.81 0.99 
 Qi5 81.0 - 91.7% 48 0.19 79 0.32 2.31 1.31-4.06 3.7x10-3 
 Totals  248  249     
          
EPIC Qi1 53.6 - 69.7% 60 0.21 49 0.21 1.00   Qi2 69.7 - 74.8% 61 0.22 51 0.22 1.02 0.60-1.74 0.96 
 Qi3 74.8 - 78.6% 58 0.19 46 0.20 0.97 0.56-1.67 0.97 
 Qi4 78.6 - 82.4% 49 0.17 38 0.16 0.95 0.54-1.68 0.95 
 Qi5 82.4 - 97.5% 55 0.19 51 0.22 1.13 0.66-1.94 0.76 
 Totals  283  235     
          
KConFab Qi1 19.0-70.2% 38 0.18 20 0.13 1.00   
 Qi2 70.2-75.4% 47 0.22 16 0.10 0.55 0.25-1.25 0.15 
 Qi3 75.4-79.1% 36 0.17 22 0.14 1.11 0.51-2.44 0.80 
 Qi4 79.1-83.0% 43 0.20 31 0.20 1.40 0.67-2.95 0.37 
 Qi5 83.0-100% 46 0.22 67 0.43 3.06 1.53-6.10 1.5x10-3 
 Totals  210  156     
          
Combined 
 
Qi1 -71.3 – -6.5% 148 0.20 104 0.16 1.00   
Qi2 -6.5 – -1.2% 148 0.20 113 0.18 1.08 0.76-1.54 0.64 
 Qi3 -1.2 – 2.5% 148 0.20 115 0.18 1.09 0.77-1.54 0.64 
 Qi4 2.5% – 6.3% 148 0.20 111 0.17 1.06 0.74-1.51 0.75 
 Qi5 6.3% –23.3% 149 0.20 197 0.31 1.89 1.36-2.64 1.6x10-4 
 Totals  741  640     
          
* Cut-off values determined by quintiles of Z-scores based on the distribution in the combined control 
population. Z-score cut off values are -0.83, -0.24, 0.19 and 0.64. 
**ORs within each study are adjusted by 5-year age categories, with further adjustment by menopausal 
status in EPIC to account for stratified sampling. ORs in combined analyses are adjusted by 5-year age 
categories and study (with EPIC defined by two categories of menopausal status to account for stratified 
sampling). 
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Table 4: Association between methylation levels in ATMmvp2a and breast cancer risk in 
combined analysis stratified by age at blood draw 
  Controls Cases Case Proportions By Study    
Age range Quintiles N Freq. N Freq. 
 (K, B, E)* OR** 95%CI P-value 
21-49 years Qi1 45 0.21 44 0.17 0.20, 0.27, 0.52 1.00   
 Qi2 51 0.23 39 0.15 0.28, 0.26, 0.46 0.68 0.37-1.25 0.21 
 Qi3 44 0.20 41 0.16 0.27, 0.32, 0.41 0.94 0.51-1.72 0.83 
 Qi4 38 0.18 44 0.17 0.43, 0.18, 0.39 1.00 0.54-2.17 0.99 
 Qi5 39 0.18 90 0.35 0.40, 0.33, 0.27 2.07*** 1.16-3.68 0.01 
 Total 217  258  0.33, 0.28, 0.38    
>49-59 years Qi1 54 0.20 27 0.13 0.19, 0.41, 0.41 1   
 Qi2 55 0.20 43 0.21 0.05, 0.49, 0.47 1.57 0.84-2.91 0.15 
 Qi3 62 0.23 48 0.24 0.19, 0.38, 0.44 1.56 0.85-2.86 0.15 
 Qi4 50 0.19 33 0.16 0.09, 0.48, 0.42 1.26 0.66-2.41 0.48 
 Qi5 49 0.18 53 0.26 0.19, 0.49, 0.32 2.25*** 1.21-4.17 0.01 
 Total 270  204  0.14, 0.45, 0.41    
>59-91 years Qi1 49 0.19 33 0.19 0.18, 0.36, 0.45 1.00   
 Qi2 42 0.17 31 0.17 0.10, 0.48, 0.42 1.00 0.51-1.97 0.99 
 Qi3 42 0.17 26 0.15 0.08, 0.62, 0.31 0.84 0.45-1.58 0.61 
 Qi4 60 0.24 34 0.19 0.26, 0.53, 0.21 0.80 0.45-1.45 0.50 
 Qi5 61 0.24 54 0.31 0.39, 0.43, 0.19 1.39** 0.87-2.26 0.27 
 Total 254  178  0.23, 0.47, 0.30    
* Study proportions for KConFab, BGS and EPIC contributing to each quintile in each age group. 
**ORs within each age-group are adjusted by study. Test for Heterogeneity of effects by age group in 
combined analysis p= 0.3109 for Qi5 vs Qi1 
***P-values for study heterogeneity for ORs comparing Qi5 vs Qi1 within age subgroups: 21-49 years 
(p=0.51), 50-59 years (p=0.73), 60-91 years (p=0.09)  
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